Company: RCUS
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001193125-25-028669
Chunk: 46

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 46
---
 unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past
financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition,
results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled
“Special Note Regarding Forward-Looking Statements.”

6

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus and the documents we have filed with the SEC that are incorporated by reference contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:

| • |     | our expectations regarding our relationship with Gilead; |

| • |     | our expectations regarding the timing and achievement of our investigational product development activities and 
 ongoing and planned clinical trials;                                                                            |

| • |     | our expectations for reporting data from clinical trials in certain timeframes; |

| • |     | our ability to develop intra-portfolio combinations and highly-differentiated small-molecule investigational                                          
 products, including our ability to create small-molecule investigational products with ideal pharmacological properties and desired clinical effects; |

| • |     | our expectations regarding the efficiency and speed with which we can create and advance small-molecule 
 investigational products and develop our investigational products and combination therapies;            |

| • |     | our reliance on third parties to conduct our ongoing and future clinical trials and third-party manufacturers to 
 manufacture and supply our investigational products;                                                             |

| • |     | our expectations regarding the nature of the immuno-oncology pathways we are targeting, the size of the potential 
 patient population and the potential market size;                                                                 |

| • |     | our ability to obtain and maintain control of our combination investigational products and maximize the 
 commercial potential of our investig